Trials / Not Yet Recruiting

Not Yet RecruitingNCT06866236

Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression

Use of NAD Oxidase Modulation Agent QRX3 for Prevention and Treatment of Progressive Chronic Kidney Disease

Status: Not Yet Recruiting
Phase: Phase 2 / Phase 3
Study type: Interventional
Enrollment: 3,000 (estimated)

Sponsor: Ebima Clifford Okundaye · Industry
Sex: All
Age: 18 Years – 90 Years
Healthy volunteers: Not accepted

Summary

Chronic kidney disease CKD is estimated to affect nearly over 800 million people globally today (with roughly 125,000 people ending up annually on dialysis in the United States alone. CKD is a contributor to illness and is associated with a diminished quality of life and reduced life expectancy . In this study the investigators are using a novel drug to target improved function of the kidneys.

Detailed description

Chronic kidney disease has been linked to impaired activity of mitochondrial dysfunction along with oxidative intracellular mechanisms that result in the cascade of progressive damage within renal tubular cells. Several treatment options for mitochondrial dysfunction have been suggested to target the loss of nephrons via renal fibrosis and tubular senescence of the kidney cells by enhancing the mitochondrial activity of these cells via the NAD/NAD+ redox pathway as well as reduce the presence of fibrogenic intracellular inflammatory markers . QRX-3 is a formulated novel drug designed to supply and optimize NAD+ mitochondrial availability and prevent this nephron loss . In this study the investigators will evaluate the effect of intervention with this novel drug therapy on chronic kidney disease CKD population with slowly declining renal function.

Conditions

Interventions

Type	Name	Description
DRUG	QRX-3	capsule

Timeline

Start date: 2025-10-01
Primary completion: 2026-10-01
Completion: 2027-07-01
First posted: 2025-03-10
Last updated: 2025-09-08

Locations

1 site across 1 country: United States

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT06866236. Inclusion in this directory is not an endorsement.